HiFiBiO Therapeutics is a clinical-stage global biotech pioneering a unique high-resolution translational solution (DIS®, Drug Intelligence Science) to enhance the probability of success for immunotherapies. DIS® combines unique single-cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS®, HiFiBiO gains an unprecedented understanding of immune modulation in human diseases driving a robust clinical pipeline of transformative immunotherapies. Additionally, HiFiBiO has partnered with major multinational pharmaceutical and biotech companies applying its innovative DIS® approach. HiFiBiO Therapeutics is headquartered in Cambridge, MA with additional operations in Paris, France, Hong Kong, Shanghai, and Hangzhou, China.